News
Innovative Cellular Therapeutics Announces Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 805 612 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Announces Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

ICT’s lead “armored” CAR-T program, ICTCAR014, demonstrated responses in two patients treated for refractory diffuse large B-cell lymphoma (DLBCL) in an investigator-sponsored clinical trial in China; safe and well-tolerated Currently in preclinical development in the U.S. for the treatment of Non-Hodgkin Lymphoma ROCKVILLE, Md., May 08, 2019 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a biotechnology…

Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDA 1366 911 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDA

ROCKVILLE, Md., March 19, 2019 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced it has successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA). At the meeting, the FDA provided feedback regarding ICT’s planned initiation of…

Innovative Cellular Therapeutics Announces Opening of U.S. Office and Appointment of New Members 1366 912 Innovative Cellular Therapeutics

Innovative Cellular Therapeutics Announces Opening of U.S. Office and Appointment of New Members

ROCKVILLE, Md., March 06, 2019 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced the opening of a U.S. office in Rockville, Maryland and the appointment of three new U.S.-based members of the executive team, a key corporate milestone for ICT. The new hires…